4例原发性肝脏神经内分泌肿瘤临床分析及文献复习

doi:10.3969/j.issn.1672-5069.2022.02.025

摘要/Abstract

摘要： 目的总结原发性肝脏神经内分泌肿瘤(PHNEN)患者的病例资料,分析其临床特征,以提高临床诊断和治疗水平。方法回顾性分析、总结我院诊治PHNEN患者的临床表现、化验检查、影像学特点、病理学检查和治疗转归。结果 4例患者均为女性,中位年龄为56(40,73)岁;2例无不适主诉,2例有腹痛;血清ALT 28.3(18.0～49.8)U/L,TBIL 11.5(9.5～16.3)μmol/L,神经元特异性烯醇化酶(NSE)为 44.1(20.2～77.1)ng/ml;腹部CT均提示肝内多发占位,增强扫描动脉期呈环形或不均匀强化,静脉期强化程度降弱;组织病理学检查示3例为神经内分泌癌,1例为神经内分泌瘤G2;1例患者接受对症治疗,采取手术、介入和/或药物等联合治疗另3例患者,随访11～81个月,2例死亡,2例生存。结论 PHNEN临床少见,缺乏特征性临床表现、辅助检查和病理学诊断标志,需排除其他病变后方可考虑诊断。早期发现和联合治疗是改善患者预后的重要策略。

关键词: 原发性肝脏神经内分泌肿瘤, 诊断, 治疗, 文献复习

Abstract: Objective The aim of this study was to summarize the clinical features of patients with primary hepatic neuroendocrine neoplasm (PHNEN). Methods The clinical manifestations, laboratory tests, imaging, pathological examination and clinical outcomes in four patients with PHNEN encountered in our hospital were summarized by retrospective analysis. Results The age of the four female patients was 56 (40-73) years; there were no symptoms in 2 cases and abdominal pain in 2 cases; serum ALT levels were 28.3(18.0-49.8)U/L, bilirubin levels were 11.5(9.5-16.3)μmol/L, neuron-specific enolase levels were 44.1(20.2-77.1) ng/ml; the abdominal CT scan showed multiple lesions in all cases, and in contrast-enhanced scan, different degrees of ring or uneven enhancement in the arterial phases, and decreased enhancement in the venous phase; all diagnoses were confirmed by pathological examination, and surgical operation, interventional therapy and chemotherapy were given in 3 cases, and one case did not receive any treatment; during the follow-up period of 11 to 81 months, 2 cases died and 2 cases still survived. Conclusion The PHNEN is a rare tumor in clinic, and lacks of specific laboratory and pathological markers. It should be considered after excluding other liver tumors. Early detection and several therapy combination are recommended to improve the prognosis.

Key words: Primary hepatic neuroendocrine neoplasm, Diagnosis, Treatment, Literature review

刘松涛, 刘梅, 渠亚超, 李瑞利, 邵晨, 闾军. 4例原发性肝脏神经内分泌肿瘤临床分析及文献复习[J]. 实用肝脏病杂志, 2022, 25(2): 251-254.

Liu Songtao, Liu Mei, Qu Yachao, et al. Primary hepatic neuroendocrine neoplasm: An analysis of 4 cases and literature review[J]. Journal of Practical Hepatology, 2022, 25(2): 251-254.

参考文献

[1] Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol,2017,3(10):1335-1342.
[2] Pathak S, Dash I, Taylor MR, et al. The surgical management of neuroendocrine tumour hepatic metastases. Eur J Surg Oncol,2013,39(3):224-228.
[3] Meng XF, Pan YW, Wang ZB, et al. Primary hepatic neuroendocrine tumor case with a preoperative course of 26 years: a case report and literature review. World J Gastroenterol,2018,24(24):2640-2646.
[4] Basuroy R, Bouvier C, Ramage JK, et al. Delays and routes to diagnosis of neuroendocrine tumours. BMC cancer,2018,18(1):1122.
[5] 中华医学会病理学分会消化疾病学组. 中国胃肠胰神经内分泌肿瘤病理诊断共识(2020版). 中华病理学杂志,2021,50(1):14-20.
[6] Yalav O, Ülkü A, Akçam TA, et al. Primary hepatic neuroendocrine tumor: Five cases with different preoperative diagnoses. Turk J Gastroenterol,2012,23(3):272-278.
[7] Yang P, Huang X, Lai C, et al. SET domain containing 1B gene is mutated in primary hepatic neuroendocrine tumors. Int J Cancer,2019,145(11):2986-2995.
[8] Zhang Z, Zhao X, Li Z, et al. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database. BMC Cancer,2021,21(1):567.
[8] Han Y, Li L, Sun H. Computed tomography and magnetic resonance imaging in the diagnosis of primary neuroendocrine tumors of the liver. World Neurosurg,2020,138:723-731.
[9] Shi C, Zhao Q, Dai B, et al. Primary hepatic neuroendocrine neoplasm: long-time surgical outcome and prognosis. Medicine(Baltimore),2018,97(31):e11764.
[10] Shah D, Mandot A, Cerejo C, et al. The outcome of primary hepatic neuroendocrine tumors: a single-center experience. J Clin Exp Hepatol,2019,9(6):710-715.
[11] Chatani PD, Aversa JG, McDonald JD, et al. Preoperative serum chromogranin-a is predictive of survival in locoregional jejuno-ileal small bowel neuroendocrine tumors. Surgery,2021,170(1):106-113.
[12] 王冬青, 曾蒙苏, 饶圣祥, 等. 原发性肝神经内分泌癌的影像表现.中华放射学杂志,2008,42(5):464-466.
[13] 张文书, 赵婧, 纪元, 等. 肝原发性与转移性神经内分泌肿瘤的临床病理分析. 中华肝胆外科杂志,2012,18(03):161-165.
[14] Jiao X, Luan W, Peng X, et al. Effects of tumor origins and therapeutic options on the prognosis of hepatic neuroendocrine tumors: a retrospective study. Medicine (Baltimore),2020,99(51):e23655.
[15] 盛若凡, 解艳红, 纪元, 等. 肝脏神经内分泌肿瘤的磁共振成像特征及分级诊断. 中华肝胆外科杂志,2015,21(4):233-238.
[16] 冯伟, 周梦豪, 张坦, 等. 原发性肝脏神经内分泌肿瘤21例临床特征和预后影响因素分析.中华肝胆外科杂志,2020,26(1):19-21.
[17] Jung J, Hwang S, Hong SM, et al. Long-term postresection prognosis of primary neuroendocrine tumors of the liver.Ann Surg Treat Res,2019,97(4):176-183.
[18] Wang HH, Liu ZC, Zhang G, et al. Clinical characteristics and outcome of primary hepatic neuroendocrine tumors after comprehensive therapy. World J Gastrointest Oncol,2020,12(9):1031-1043.
[19] Kotteas EA, Syrigos KN, Saif MW. Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. Onco Targets Ther,2016,9:699-704.
[20] Qi Z, Tan H. Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis. Biosci Rep,2020,40(3):BSR20194127.
[21] Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol,2020,21(11):1500-1512.
[22] Nikeghbalian S, Eshraghian A, Kazemi K, et al. Liver transplantation for high-grade primary hepatic neuroendocrine tumor with diffuse liver metastasis. J Gastrointest Cancer,2020,51(1):304-306.